Format

Send to

Choose Destination
J Clin Med. 2015 Aug 14;4(8):1612-30. doi: 10.3390/jcm4081612.

Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients.

Author information

1
Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet avenue, Moncton, NB E1A 3E9, Canada. evl6741@umoncton.ca.
2
Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet avenue, Moncton, NB E1A 3E9, Canada. pier.morin@umoncton.ca.

Abstract

The growing attention that non-coding RNAs have attracted in the field of cancer research in recent years is undeniable. Whether investigated as prospective therapeutic targets or prognostic indicators or diagnostic biomarkers, the clinical relevance of these molecules is starting to emerge. In addition, identification of non-coding RNAs in a plethora of body fluids has further positioned these molecules as attractive non-invasive biomarkers. This review will first provide an overview of the synthetic cascade that leads to the production of the small non-coding RNAs microRNAs (miRNAs) and presents their strengths as biomarkers of disease. Our interest will next be directed at exploring the diagnostic utility of miRNAs in two types of cancer: the brain tumor glioblastoma multiforme (GBM) and breast cancer. Finally, we will discuss additional clinical implications associated with miRNA detection as well as introduce other non-coding RNAs that have generated recent interest in the cancer research community.

KEYWORDS:

breast cancer; cancer diagnosis; cancer therapeutics; glioblastoma multiforme; glioma; long non-coding RNAs; microRNAs; non-coding RNAs

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center